Bayer Aktiengesellschaft (BAYRY) to Release Quarterly Earnings on Tuesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) will likely be posting its resultson Tuesday, August 4th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.23 per share and revenue of $12.3123 billion for the quarter. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Stock Performance

BAYRY stock opened at $13.39 on Tuesday. The stock’s 50 day simple moving average is $12.11 and its 200 day simple moving average is $12.00. Bayer Aktiengesellschaft has a 12-month low of $7.19 and a 12-month high of $15.23. The firm has a market cap of $52.62 billion, a P/E ratio of -20.92, a P/E/G ratio of 4.21 and a beta of 0.55. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

A number of brokerages have weighed in on BAYRY. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Finally, DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.